LeadingAge’s president and CEO has asked Congress to ensure access to COVID-19 tests, vaccines and treatments in letters supporting the White House’s request for COVID-19 supplemental funds.
Clinical briefs for Friday, April 29
By
Alicia Lasek (f3)
Apr 29, 2022
CDC to update NHSN vaccine reporting requirements for nursing homes … Paxlovid “rebound” anecdotes concern patients, providers … Nasogastric tube feeding raises odds of pneumonia in advanced dementia...
Clinical briefs for Thursday, Jan. 6
By
Alicia Lasek
Jan 06, 2022
Fourth COVID-19 vaccine dose boosts antibodies fivefold in Israeli study … ICUs may be spared omicron surge, investigation finds … New anemia drug for kidney dialysis patients may be approved in 2022...
Omicron renders Pfizer vaccine less effective; variant surge to hit U.S. by January
By
Alicia Lasek
Dec 15, 2021
The vaccine is less able to prevent infection, but retains 70% protection against hospitalization, a new study shows. The news comes as federal health officials warn that omicron is spreading rapidly in...
First human trial of nasal vaccine for Alzheimer’s set to begin in Boston
By
Alicia Lasek
Nov 18, 2021
Sixteen participants with early, symptomatic Alzheimer’s will receive doses of a vaccine containing the immune-modulating drug Protollin. Nasal delivery has shown promise as a way to eliminate beta amyloid...
J&J asks for booster go-ahead, says second vaccine dose provides 100 percent COVID protection
By
Alicia Lasek
Oct 07, 2021
A second shot of Johnson & Johnson’s vaccine provides 100% protection against severe or critical COVID-19 when given two months after a first dose, according to new data.
RSV shot prevents pneumonia with 80 percent efficacy in older adults, J&J says
By
Alicia Lasek
Oct 05, 2021
A vaccine candidate developed to protect vulnerable adults against the common respiratory syncytial virus has shown 80% efficacy in reducing the risk of dangerous lower respiratory tract diseases such...
FDA may authorize half-dose booster of Moderna’s coronavirus vaccine
By
Alicia Lasek
Sep 30, 2021
A 50-microgram dose appears to be effective enough to increase waning vaccine protection, and may reduce the risk of side effects, sources tell investigators.
Vaccine potency wanes, but third COVID shot restores 95 percent efficacy, new data show
By
Alicia Lasek
Sep 16, 2021
New data from vaccine maker Pfizer and Israel’s health ministry may help U.S. health agencies make a case for recommending COVID-19 booster shots, various sources report.